<DOC>
	<DOCNO>NCT00698607</DOCNO>
	<brief_summary>Objectives 1 . To evaluate safety long-term effectiveness coronary stenting Everolimus-eluting coronary stent system ( EECSS ) ( XIENCETM V , Abbott Vascular , Santa Clara , CA , PromusTM , Boston Scientific , Natick , MA ) , compare sirolimus-eluting coronary stent system ( SECSS ) ( CypherTM , Cordis Johnson &amp; Johnson , Warren , NJ ) treatment coronary stenosis . 2 . To evaluate safety efficacy 6-month clopidogrel therapy compare 12-month clopidogrel therapy . Study Design : Prospective , open label , two-arm , randomize multi-center trial test non-inferiority EECSS compare SECSS , test non-inferiority 6 month duration compare 12 month duration clopidogrel therapy . Patients randomize two two factorial manner accord type drug elute stent ( EECSS vs. SECSS ) duration dual anti-platelet therapy ( 6 month vs. 12 month ) . Randomization also stratify per hospital presence DM presence long lesion ( lesion length ≥ 28mm ) Patient Enrollment : 1,372 patient enrol 17 center Korea . Patient Follow-Up : Clinical follow-up occur 1 , 3 , 9 month , 1 , 2 , 3 , 4 , 5 year . Investigator designee may conduct follow-up telephone contact office visit . Primary Endpoint - In-segment late luminal loss ( LL ) 9 month comparison stenting EECSS vs. SECSS . - Target vessel failure ( TVF ) ( cardiac death , myocardial infarction , ischemia driven target vessel revascularization ) 12 month comparison 6 month vs. 12 month clopidogrel therapy Secondary Endpoint - All Death - Cardiac death - Myocardial infarction - Target vessel revascularization ( TVR ) ( ischemia-driven ) - Target lesion revascularization ( TLR ) ( ischemia-driven ) - Stent thrombosis - Acute success ( device , lesion , procedure ) - Bleeding - Cerebrovascular accident - In-stent LL 9 month - Angiographic pattern restenosis 9-month angiographic follow-up - In-stent in-segment % diameter stenosis ( % DS ) 9 month - In-stent % volume obstruction ( % VO ) 9 month - Incomplete stent apposition post index procedure - Persisting incomplete stent apposition , late-acquired incomplete stent apposition , aneurysm , thrombosis , persist dissection 9 month</brief_summary>
	<brief_title>Efficacy Xience/Promus Versus Cypher rEducing Late Loss After stENTing</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>General 1 . Subject must least 18 year age . 2 . Subject able verbally confirm understandings risk , benefit treatment alternative receive XIENCE V EECS he/she his/her legally authorize representative provide write informed consent prior study related procedure . 3 . Subject must significant coronary artery stenosis ( &gt; 50 % visual estimate ) 4 . Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia . In subject coronary artery stenosis &gt; 75 % , evidence myocardial ischemia document . 5 . Subjects must acceptable candidate Coronary Artery Bypass Graft ( CABG ) surgery . Angiographically Inclusion Criteria 1 . Target lesion ( ) must locate native coronary artery visually estimate diameter ≥ 2.25 mm ≤ 4.25 mm . 2 . Target lesion ( ) must amenable percutaneous coronary intervention General 1 . The patient know hypersensitivity contraindication follow medication ( heparin , aspirin , clopidogrel , sirolimus , everolimus , Contrast medium 2 . Systemic ( intravenous ) Sirolimus , everolimus use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 5 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 6 . Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL . 7 . An elective surgical procedure plan would necessitate interruption clopidogrel first 12 month post enrollment . 8 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 9 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 10 . Patients receive stent implantation target vessel prior enrollment . 11 . Patients LVEF &lt; 25 % cardiogenic shock 12 . Patients myocardial infarction within 72 hour 13 . Creatinine level ≥ 3.0mg/dL dependence dialysis . 14 . Severe hepatic dysfunction ( AST ALT : 3 time upper normal reference value ) . Angiographic Exclusion Criteria 1 . Patients significant leave main coronary artery stenosis 2 . Patients 's target lesion instent restenosis stented segment drugeluting stent bare metal stent 3 . Target lesion chronic total occlusion 4 . True bifurcation lesion require two stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>